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Abstract 
Aortic valve replacement (AVR) is the most frequently performed procedure in valve surgery. 
The controversy about the optimal choice of the prosthetic valve is as old as the technique 
itself. Currently there is no perfect valve substitute available. The main challenge is to 
choose between mechanical and biological prosthetic valves. Biological valves include  
pericardial (bovine, porcine or equine) and native porcine bioprostheses designed in stented 
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or stentless versions. Homografts and pulmonary autografts are reserved for special 
indications and will not be discussed in detail in this review. We will focus on the decision 
making between artificial biological and mechanical prostheses, respectively.                                                                                                                                            
The first part of this article reviews guideline recommendations concerning the choice of 
aortic prostheses in different clinical situations while the second part is focused on novel 
strategies in the treatment of patients with aortic valve pathology. 
 
Keywords: aortic valve replacement, biological valve prosthesis, mechanical valve 
prosthesis, oral anticoagulation, novel oral anticoagulants. 
 
 
Current Evidence 
 
The current guidelines of the European Society of Cardiology from 2012 [1] and of the 
American Heart Association from 2014 [2] uniformly recommend mechanical aortic valve 
replacement (AVR) in patients under 60 years of age and biologic AVR in patients over 70 
years of age (Fig. 1). In patients between 60 and 70 years of age, recommendations are 
conflicting. The ESC-Guidelines recommend biologic prosthesis from the age of 65 years 
onwards, whereas the newer AHA/ACC guidelines only recommend biological valves starting 
with 70 years of age. Looking at the development of the guidelines over the last 20 years 
there is a shift away from a clear-cut age limit towards the patients wish and life-style 
considerations. 
Currently there is a trend towards more biological AVR, also in patients under 65 years of 
age, which is contrary to the progress of life expectancy of patients at this age. 
Justification for this approach is the option for a valve-in-valve procedure in the case of 
structural valve deterioration (SVD) which might become a routine bail out strategy. In 
addition, the last generation of pericardial tissue valves may have excellent long-term 
durability over 20 years. However, current studies also demonstrate a significant age-
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dependency in durability with lower rates of SVD when implanted in increased age [3,4]. The 
conclusion to implant biological valves at a younger age could therefore be contra-
productive.  Another limitation is, that several valves on market show significant shorter long-
term results with SVD already in less  than 10 years after implantation. 
 
In literature, most clinical studies demonstrate higher rates of reoperation and decreased 
survival after biological AVR compared to mechanical AVR. 
Bourguignon et al. identified both the cumulative risk of reoperation due to SVD and the 
patient’s age at surgery as the unique covariate for survival [3]. 
With future life expectancies of > 85 years, prosthetic valve durability of at least 15 to 20 
years will be needed in a 65 years old patient in order to avoid re-interventions. The 
probability of reoperation due to SVD after 20 years in a 65 years old patient is higher than 
15% [3]. 
The ad hoc argument for the use of biological valves in younger patients is often the 
possibility of valve-in-valve procedures, when SVD occurs. However, this is not justified by 
data, yet. Larger clinical studies are rare in this field and the reports present only a limited 
number of prostheses types [5-7]. In addition, the large Valve-in-valve registry demonstrates 
a high rate of patient-prosthesis mismatch, especially when implanted in a valve smaller than 
25mm [8]. Valve-in-valve procedures should therefore only be performed under study-
protocol or registries to analyze long-term  results. 
One principal problem is the lack of long-term data after transcatheter aortic valve 
implantation (TAVI). There are only few studies available on durability or rate of SVD with 
follow-up times beyond 5 years [9,10]. At this time, it is unclear if transcatheter valves have 
durability comparable with the last generation of surgical valve prostheses, and some reports 
raise doubts. With a 5-year overall mortality of around 50% after transcatheter valve 
implantation, it will be difficult to show a non-inferiority in durability compared with surgical 
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implanted  biologic valves, because of a low number of survivors in TAVI cohorts. 
 
 
 
The major limitation with mechanical prostheses is the required life-long anticoagulation with 
subsequent complications. Valve thrombosis, thromboembolic events and bleeding events 
account for 75% of all complications that occur after mechanical heart valve replacement.  
In the current guidelines, antiplatelet agents are recommended additionally to vitamin K 
antagonists (VKA) as a protective factor against thromboembolic events [2,11]. There was a 
reduction in thromboembolic events in patients with additional antiplatelet therapy. Several 
studies showed that the risk of thromboembolic events are similar between biological and 
mechanical valve prostheses and can be reduced by administering antiplatelet agents [12-
14]. Self-management of oral anticoagulation with self-measuring of the INR (international 
normalized ratio) may reduce the rate of thromboembolic events, but showed no difference in 
bleeding complications [15,16]. 
New oral anticoagulants are not applicable in patients with valve prosthesis. Studies had to 
be terminated due to adverse outcome with higher rates of thromboembolic events and 
higher risk of bleeding compared to standard warfarin  therapy [17]. 
Furthermore, the selection of the valve prosthesis depends on various patient-related factors, 
such as age at implantation, compliance with long-term anticoagulation, risk factors for and 
history of bleeding events, life expectancy, life-style and the patient’s preferences. 
Concerning the need for anticoagulation after valve replacement with a mechanical valve, it 
has to be taken into account that a substantial number of patients after biological valve 
replacement need oral anticoagulation as well by other indications mainly due to the onset of 
atrial fibrillation. In a prospective study of over 6000 participants, lifetime risk to develop AF 
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at the age of 55 years was already 23.8% in men and 22.2% in women. This is increased 
with concomitant cardiovascular, structural heart disease and age [18,19]. 
 
 
 
Randomized trials comparing biological and mechanical valve replacements are rare.  
Stassano et al. randomized 310 patients between 55 and 70 years of age into a mechanical 
and a biological prosthesis group to undergo AVR. They found similar mortality and major 
adverse prosthesis-related events (thromboembolism, bleeding, endocarditis, SVD, 
nonstructural dysfunction) in the two groups over a mean follow up of just over 4 years [20]. 
Brown et al. analyzed outcome after AVR with mechanical versus biological prosthesis in 
patients aged 50 to 70 years at operation. Freedom from reoperation at 10 years was 98% 
for mechanical valves and 91% for bioprostheses (p=0.06) [21]. Rates of late stroke or other 
embolic events and of endocarditis were similar between the two groups. Rehospitalisation 
because of hemorrhagic events occurred in 15% of patients with mechanical valves and 7% 
of patients with bioprostheses (p = 0.01). The 5- and 10-year unadjusted survivals were 87% 
and 68% for mechanical valves and 72% and 50% for bioprostheses, respectively (P < 0.01). 
With this superior survival of the patient group after mechanical AVR the authors conclude 
that there is insufficient evidence to recommend bioprosthetic valves in the aortic position for 
patients younger than 65 years.  
In accordance with this data, Weber et al.  conclude from a cohort of patients younger than 
60 years old that biologic aortic valve replacement is associated with reduced mid-term 
survival compared with survival after mechanical aortic valve replacement. Survival was 
significantly reduced in patients after biologic aortic valve replacement (90.3% vs 98%; P = 
0.038) [22].  
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The latest trial by a Swedish group showed the same results with better long-term survival in 
patients aged 50-69 years after AVR with mechanical valves compared with those who had 
received bioprostheses. Additionally they analyzed age subgroups and showed a significant 
difference in cumulative survival in the subgroup 50-59 years compared with no significant 
difference in the age group 60-69 years [23]. 
 
Infective endocarditis 
Infective endocarditis (IE) has a high mortality rate, even with appropriate antibiotic and 
surgical therapy. The risk of IE is 50 times higher in patients with a prosthetic valve 
compared with the general population. In developed countries, IE is most often associated 
with prosthetic valves and intracardiac devices. Prosthetic valve endocarditis (PVE) is 
reported to occur with a 0.3% to 1.2% patient-year incidence. It accounts for 10-30% of all 
cases of IE. [2].   
Both mechanical and bioprosthetic valves can be involved by the infection and their rate of 
infection is similar at 1 year. In the long-term biological prostheses seem to have a higher 
incidence of PVE compared to mechanical prostheses [24].  This was again confirmed in   a 
recent study by Brennan et al. They reported a 12-year incidence of rehospitalisation for 
endocarditis of 2.2% for patients with bioprosthesis versus 1.4% after mechanical AVR . This 
has been explained by the fact that a degenerating  valve alone presents a risk factor for 
PVE [25]. 
In patients suffering from IE the optimal timing and the choice of substitute - homograft, 
biological or mechanical valve prosthesis - is complex and studies are conflicting. Operative 
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mortality is similar in mechanical and biological AVR [1]. The 2 to 3% risk of reinfection 
during valve replacement is not as high as the mortality rate of IE without surgical therapy 
which is as high as 51% [26].  
 
 
Nguyen et al. compared a total of 167 patients with IE undergoing AVR with biological (18%),  
mechanical prosthesis (65%) or with a homograft (16%). They found a lower 5-year survival 
with bioprosthesis than after AVR with mechanical prosthesis in patients up to 65 years of 
age. However,  no significant difference between the two groups was present in patients over 
65 years of age. Homografts showed no difference from mechanical valves in both age 
groups [27]. 
 
Moon et al. reported in an epidemiological study a rate of recurrent or residual endocarditis of 
1.5% per patient-year for native valve endocarditis and 2.5% for prosthetic valve 
endocarditis. There was no significant difference in endocarditis rates between mechanical 
(1.2%) and bioprosthetic (1.8%) valve substitutes. Operative mortality and complication-free 
survival were also similar within the two valve types [28]. 
Based on this data we recommend to replace infected valves, whether native or prosthetic, 
with a mechanical prosthesis in younger patients and with a biological prosthesis in patients 
older than 70 years or with limited life expectancy as recommended in the AHA guidelines for 
normal AVR without any infection. Between 60 and 70 years of age, it depends on other risk 
factors, bleeding complications in the history and life expectancy. 
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Bleeding 
Mechanical heart valves produce abnormal flow with areas of low flow as well as areas with 
high flow and subsequent high shear stress which can cause platelet activation. To prevent 
valve thrombosis and to minimize the risk of thromboembolic events, patients with 
mechanical AVR receive life-long oral anticoagulation therapy with vitamin K antagonists 
(VKA). [2,25,29].  
When low-dose aspirin (75 to 100mg daily) is administered additionally to VKA, the risk of 
major emboli can be reduced from 8.5% to 1.9% (OR 0.43; 95% CI: 0.32 to 0.59), the risk of 
stroke from 4.2% to 1.3% and the overall mortality from 7.4% to 2.8% (OR 0.57; 95% CI: 
0.42 to 0.78). The risk of major bleeding, however, is increased when antiplatelet agents are 
added to oral anticoagulants (OR 1.58; 95% CI: 1.14 to 2.18) [29]. 
VKA administration with target INR 2-3 was compared with high degree anticoagulation with 
INR target 3-4. The thromboembolic event rate was not reduced significantly in the high dose 
group, but the bleeding risk could be reduced significantly with low dose anticoagulation (INR 
2-3) [30]. Comparable results were found with additional antiplatelet therapy. The risk of 
gastro-intestinal irritation or hemorrhage is dose dependent, but the antiplatelet effect is not. 
The benefit of higher dose aspirin (> 100mg) is not superior to low-dose aspirin (75 to 
100mg), but the risk of major bleeding is significantly increased in the high-dose group. 
Consequently the AHA Guidelines from 2013 recommend oral anticoagulation with target 
INR of 2.5 (2.0 to 3.0) for mechanical prosthesis in aortic position combined with low-dose 
aspirin 100mg daily [2,29]. 
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The remaining annual risk of thromboembolic events in patients with a mechanical valve 
prosthesis is 1-2% compared with 0.7% with a bioprosthesis. 
 
Valve choice in women of child-bearing age 
Women with a prosthetic heart valve have a higher rate of adverse outcomes than expected 
in a general obstetric population. This includes maternal mortality, miscarriage, 
thromboembolism and obstetric hemorrhage. Infants of these women are at an increased risk 
of perinatal mortality, preterm birth, small-for-gestational-age and congenital malformations 
[31,32]. The selection of prosthesis is a major challenge in women with the desire to have 
children. The 2012 ECS-Guidelines emphasized the high risk of thromboembolic 
complications with a mechanical prosthesis during pregnancy despite correct 
anticoagulation. A planned pregnancy is considered a class IIa and level C evidence [33] for 
the implantation of a bioprosthesis. 
After biological AVR  the majority of patients will need a reoperation within the next 8 to 10 
years. There are conflicting data of accelerated deterioration of prosthetic heart valves during 
pregnancy [28]. However,  in this very young age group, even without accelerated 
deterioration by pregnancy, the durability of bioprostheses is limited [3,20]. Comparing the 
mortality of reoperation in this patient population with the overall risk of VKA, there is a 
mortality of around 6% for reoperation and around 5% in patients taking VKA [31,33]. 
Women with a mechanical valve-prosthesis have two major problems: (1) a hyper-coagulable 
state exists throughout pregnancy resulting in a higher risk of thromboembolic complications 
and (2) vitamin K antagonists (VKA) cross the placenta, increasing the risk of early abortion, 
embryopathy and prematurity. There are reports of teratogenity of VKA in the first trimester of 
pregnancy with higher rates of spontaneous abortion under VKA [34]. The incidence of 
embryopathy is still debated and the teratogenic effect of VKA may be masked by the high 
rate of miscarriages and therapeutic abortions [35]. During delivery there is a higher risk of 
intracranial bleeding. Van Hagen et al. compared 212 patients with a mechanical valve with  
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134 patients with a tissue heart valve and 2620 patients without a prosthetic valve. Women 
with a mechanical heart valve had only a 58% chance of an uncomplicated pregnancy with a 
live birth [36]. 
Timing of AVR and pregnancy is an important factor. If AVR is performed with a 
bioprosthesis, pregnancy should be planned within the next few years because of expected 
durability of only 7 to 10 years. If there is a severe deterioration of the prosthetic valve with 
the need for reoperation during pregnancy, it will be a high-risk operation with a fetal 
mortality of 30% to 40% and a maternal mortality rate of up to 9%. 
 
Renal Insufficiency 
Patients with end stage renal disease (ESRD) suffer from chronic uremia, hypertension and 
hyperlipidemia and need frequent vascular access together with impaired immunity, which 
lead to a heightened risk of endocarditis. All these factors lead to a high cardiac mortality and 
morbidity and to a poor survival, with a 5-year mortality rate of approximately 65% [37,38]. If 
a patient suffers additionally from diabetes or coronary artery disease, the survival rate is 
even lower. 
Earlier studies reported high bleeding complications in patients with ESRD. Okada et al. 
showed that the bleeding rate is age dependent with higher rates in older patients. If they 
were matched in age groups, there were no significant differences in bleeding rates between 
biological and mechanical prosthesis. But they reported a significant difference in bleeding 
complications between patients under dialysis versus non-dialysis patients [38,39]. 
Data on SVD in patients with ESRD are lacking, mainly because of a low survival rate in this 
patient group. Studies showed low rate of SVD, but with a mean follow-up of only 5 years. 
Even with accelerated valve failure, this time is too short to demonstrate significant 
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differences. An important comorbidity in ESDR is secondary hyperparathyroidism. Okada et 
al. describe a very strict management of patients with secondary hyperparathyroidism. They 
performed a parathyroidectomy, when the patient could not be controlled with aggressive 
medication. Indications for heart valve replacement in patients with ESRD are the same as in 
patients with normal renal function. But the choice of optimal valve prosthesis is a subject of 
debate. 
 
Previous guidelines recommended mechanical valve prostheses in patients with ESRD 
because of the general concern that bioprosthetic valves undergo premature failure caused 
by accelerated calcification. This concern is not well-founded and there are only few reports 
which could not be confirmed in newer studies. 
Regarding recent studies, the choice between bioprosthetic and mechanical valves can be 
recommended with the same decision criteria as in patients with normal renal function and 
should be oriented primarily on age and life expectancy. Whereas a younger patient under 
dialysis without important comorbidities has a realistic survival rate to experience SVD, a 
patient in his seventies with diabetes has a poor survival and won’t experience SVD even 
with accelerated valve deterioration caused by increased calcium level. At the same time 
patients on chronic dialysis tend to have more hemorrhagic events. Therefore, the choice in 
these patients will be in favor of a biological valve replacement even in patients under the 
age of 65 years [2,40]. 
 
Expert commentary 
 
The necessity to choose between a mechanical and biological valve is due to the necessity 
to anticoagulate mechanical valves. The invention of a valve without the need for 
anticoagulation would alter strategies of valve choice. Despite a long history of success the 
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search for the ideal replacement valve is ongoing. The ideal prosthetic valve would combine 
high performance, lack of turbulence, risk free implantation and no maintenance. Present 
tissue valves fall short of these ideals as 15% will fail after 20 years in patients receiving 
them at the age of 65 years [3]. The inconvenience of warfarin and the annual risk of 
bleeding (1-2%) make mechanical valves also fall short of this ideal [29]. 
The medical industry is not only innovative in biological valve design, but also in mechanical 
valve prostheses. There are some new designs available. The main goal will be to reduce 
thrombogenity, so that it would be possible to reduce INR targets. The biggest challenge will 
be, not to pay these lower INR-targets with higher rates of thromboembolic events. 
With the On-X aortic heart valve (Fig. 2) a valve prosthesis with recommended lower INR-
target is available. Very recently, the On-X mechanical heart valve (On-X Life Technology 
Inc.) has received U.S. FDA clearance for an expanded labeling claim that allows patients 
with On-X aortic heart valves to be managed at an INR level of 1.5 to 2.0, the lowest rate for 
any other mechanical valve. Patients experienced a 65% overall reduction in bleeding events 
with no increase in stroke rate [41].  
The Lapeyre-Triflo FURTIVA® is similar to the On-X aortic valve a further step into finding the 
ideal mechanical prosthesis (Fig. 3). Due to an innovative anatomic tri-leaflet design with a 
physiological operating mode and being composed of high-performance biocompatible 
materials, FURTIVA® may be the first prosthetic heart valve resistant to both thrombosis and  
 
 
structural failure which at the same time functions without warfarin anticoagulation therapy 
[42].  
New mechanical valve types will also have their effect on the treatment on women of child-
bearing age. Only limited data exists on outcomes of contemporary pregnancies in the 
setting of maternal heart valve prostheses. Most of the reviews are still based on 
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pregnancies from the previous four decades including ball-and-cage valves with high 
anticoagulation management [43,44].   
A recent review by Lawley et al. [32] is the first to investigate these questions in a 
contemporary setting defined as the last 20 years.  The current review showed that no 
deaths occurred due to valve thrombosis reflecting improvement in prosthesis design and 
management.   Although outcomes have improved considerably the main question is still left 
unanswered. How does one balance the increased risk of mortality and thrombosis during 
pregnancy in women with mechanical valves against the need for more frequent valve 
replacement with bioprosthetic devices? One can only speculate that modified 
anticoagulation regimes and new valve types like the above mentioned On-X and Lapeyre 
Triflo FURTIVA® might push the balance toward a mechanical AVR in women of child-
bearing age in the future. 
When implanting mechanical valves most surgeons promise their patients that in the near 
future there will be patient friendly alternatives to warfarin. Novel oral anticoagulants like 
dabigatran (direct thrombin inhibitor) where thought to fulfill these promises as their use in 
patients with atrial fibrillation and animal studies suggested a potential role in patients with 
mechanical heart valves.  
The RE-ALIGN study was the first randomized study to validate a dabigatran dosing regimen 
for the prevention of thrombosis in mechanical heart valve patients. The trial was prematurely 
terminated due to excess bleeding events in patients receiving dabigatran. It was not as 
effective as warfarin for the prevention of thromboembolic complications [17].   
Whether other novel anticoagulants such as rivaroxaban and apixaban (factor Xa inhibitors) 
would result in better outcomes compared with dabigatran needs to be investigated. 
It has to be emphasized that none of the current valves available can fully restore native 
valve function due to their lack of growth and remodeling capabilities. Heart valve tissue 
engineering tries to overcome these limitations. Trileaflet heart valve tissue engineering aims 
to develop valve substitutes in vitro or situ, by using the regenerative potential of the body for 
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the tissue culture phase. The journey to a truly autologous tissue-engineered heart valve is 
still been a long one but there is very promising progress [45,46]. 
 
Five-year view 
The next five years will mainly be marked by the development of TAVI. If the industry is able 
to reduce pacemaker rates and paravalvular leakage and studies are able to present 
freedom from structural valve degeneration of over 10 years, TAVI will most surely become 
an option for younger patients and therefor will influence the choice between biological 
valves and mechanical valves in view of the valve-in-valve option. 
These trends would surely be influenced by the development and launch of an 
anticoagulation free mechanical valve and suitable NOAKs. The goal in the end will be to 
provide every patient with one life-long solution without having to worry about valve 
degeneration, thrombosis and re-intervention. 
 
 
 
Key issues 
 
 
 Current guidelines recommend mechanical aortic valve replacement (AVR) in 
patients under 60 years of age and biological AVR in patients over 70 years of age. In 
patients between 60 and 70 years of age, recommendations are conflicting. 
 Looking at the development of the guidelines over the last 20 years there is a shift 
away from a clear-cut age limit towards the patients wish and life-style 
considerations. 
 The probability of reoperation due to structural valve deterioration of a tissue valve 
after 20 years in a 65 years old patient is > 15%. 
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 Valve-in-valve treatment is still experimental and should carefully be addressed in the 
decision-making progress when it comes to implanting biological valves at an earlier 
age.  
 In the current guidelines, antiplatelet agents are recommended additionally to vitamin 
K antagonists as a protective factor against thromboembolic events. 
 Both mechanical and bioprosthetic valves can be involved by the infection and their 
rate of infection is similar at 1 year. In the long-term biological prostheses seem to 
have a higher incidence of PVE compared to mechanical prostheses.  
 The annual risk of thromboembolic events in patients with a mechanical prosthesis is 
1-2% versus 0.7% with a bioprosthesis even with appropriate antithrombotic therapy. 
 Women with a prosthetic heart valve have a higher rate of adverse outcomes than 
expected in a general obstetric population. 
 In patients with renal insufficiency the choice  of valve type can be made with the 
same decision criteria as in patients with normal renal function. 
 New mechanical prostheses allow lower INRs and, one day, maybe no 
anticoagulation at all. The biggest challenge will be, not to pay these lower INR-
targets with higher rates of thromboembolic events. 
 Modified anticoagulation regiments and new valve types might in the future push the 
balance toward a mechanical AVR in in women of child-bearing age.  
 The use of novel oral anticoagulants in patients with mechanical heart valves should 
be avoided at this time. 
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Figure 1. Comparison between guidelines for the treatment of patients with valvular heart 
disease of the American Heart Association (AHA) / American College of Cardiology (ACC) 
2014 and the European Society of Cardiology (ESC) 2012 
 
 
 AHA/ACC 2014 ESC 2012 
Guidelines COR LOE Age COR LOE Age 
Choice of prosthetic valve type should be a shared 
decision process, considering the desire of the informed 
patient 
I C  I C  
A mechanical prosthesis is recommended IIa B < 60 IIa C < 60 
A bioprosthesis is reasonable IIa B > 70 IIa C > 65 
Either a mechanical or a bioprosthetic valve is 
reasonable 
IIa B 60 - 
70 
IIa C 60 - 
65 
Bioprosthesis in women with desire to have children    IIa C  
       
 
 
 
ACC, American College of Cardiology; AHA, American Heart Association; COR, class of 
recommendation; LOE, level of evidence. 
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Figure 2. On-X aortic heart valve (On-X Life Technologies, Inc.) 
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Figure 3. Lapeyre-Triflo FURTIVA® 
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